Seagen(SGEN) - 2020 Q2 - Earnings Call Presentation

Financial Performance - Total revenues for Q2 2020 were $278 million[6,19] - Net product sales in Q2 2020 increased by 51% to $240 million compared to Q2 2019[18] - ADCETRIS net product sales were $167.5 million in Q2 2020[19] - PADCEV net sales increased 66% from Q1 2020 to Q2 2020[10] - TUKYSA achieved $15.8 million in sales in Q2 2020 following its mid-April approval[10] 2020 Financial Outlook - ADCETRIS U S and Canada net product sales are projected to be $675 to $700 million[27] - PADCEV U S net product sales are projected to be $215 to $235 million[27] - R&D expenses are expected to be $820 to $870 million[27] Clinical Development - Reported positive topline data for Tisotumab Vedotin (TV) in recurrent/metastatic cervical cancer, with a 24% ORR [95% CI: 15.9%-33.3%][36,38]